

Integrum Q1 - Continuing on the positive trajectory

Redeye notes another quarter where Integrum is delivering well on its organizational and commercial intensification with a clear US focus, which we believe will continue driving its sales growth for the coming years. We reiterate our SEK 104 Base Case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

Integrum Q1 - Continuing on the positive trajectory